Clinical Trials - Leukemia

Type 

 Trial

 Phase Contact Location
 AML Phase I/II Trial of Azacitidine Plus Lenalidomide in the Treatment of Acute Myeloid Leukemia  I/II  Rose Hoyt  Nebraska Medical Center, Omaha, NE
 CMML  A Phase II Study of the Efficacy, Safety and Determinants of Response to 5-Azacitidine (Vidaza) in Patients with Chronic Myelomonocytic

Leukemia (CMML)

 II Rose Hoyt  Nebraska Medical Center, Omaha, NE
 AML  AAML1031 A Phase III Randomized Trial for Patients with de novo AML using Bortezomib and Sorafenib (IND#114480; NSC# 681239, NSC#724772) for Patients with High Allelic Ratio FLT3/ITD  III Tamra Olson  Nebraska Medical Center, Omaha, NE
 APL  S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients with Previously Untreated High-Risk Acute Promyelocytic Leukemia  II  Rose Hoyt  Nebraska Medical Center, Omaha, NE
 ALL  A Phase II Study of Dasatinib (SPRYCEL) (IND #73969, NSC #732517) as Primary Therapy Followed by Transplantation for Adults = 50 Years, with Newly Diagnosed PH+ Acute Lymphoblastic Leukemia by CALGB, ECOG, SWOG and NCIC CTG (CALGB 10701)  II Rose Hoyt  Nebraska Medical Center, Omaha, NE
 CLL  Phase II Study of Reduced-Intensity Allogeneic Stem Cell Transplant for High-Risk Chronic Lymphocytic Leukemia (CLL) (CALGB 100701-02)  II  Penny Hardiman  Nebraska Medical Center, Omaha, NE
 AML  AAML05P1, Killer Immunoglobulin-Like Receptor (KIR) Incompatible Unrelated Donor Hematopoietic Stem Cell Transplantation (SCT) for AML with Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory and Relapsed Acute Myelogenous Leukemia (AML) in Children: A Children's Oncology Group (COG) Study   Tamra Olson  Nebraska Medical Center, Omaha, NE
 ALL  AALL1131, A Phase III Randomized Trial for Newly Diagnosed High Risk B-Precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC# 606869) in the Very High Risk Stratum  III Tamra Olson  Nebraska Medical Center, Omaha, NE
 T-CELL  AALL0434, Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults with Newly Diagnosed T-cell Acute Lymphoblastic Leukemia (CHMC IRB#515-0207/UNMC 027-08)   Tamra Olson  Nebraska Medical Center, Omaha, NE
 AL  ACCL0934 - A Randomized Trial of Levofloxacin to Prevent Bacteremia in Children Being Treated for Acute Leukemia (AL) or Undergoing Hematopoietic Stem Cell Transplantation (HSCT)    Nancy Berounsky  Nebraska Medical Center, Omaha, NE
 ALL  AALL0932, Treatment of Patients with Newly Diagnosed Standard Risk B-Precursor Acute Lymphoblastic Leukemia (ALL) (UNMC 512-10)   Tamra Olson  Nebraska Medical Center, Omaha, NE
 AML  ACCL0933, A Randomized Open-Label Trial of Caspofungin Versus Fluconazole to Prevent Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML) (UNMC 598-11)   Tamra Olson  Nebraska Medical Center, Omaha, NE
 AML AAML1031, A Phase III Randomized Trial for Patients with De Novo AML using Bortezomib (IND# 58443, NSC# 681239) and Sorafenib (BAY43-9006, IND# 69896, NSC# 724772) for Patients with High Allelic Ratio FLT3/ITD (SRC-PO)  III Tamra Olson  Nebraska Medical Center, Omaha, NE
 AML A Phase III Randomized Study of Oral Sapacitabine in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia  III Rose Hoyt  Nebraska Medical Center, Omaha, NE
 ALL A Phase 3, Multicenter, Randomized Study to Evaluate the Substitution of Marqibo (Vincristine Sulfate Liposomes Injection, VSLI) for Standard Vincristine Sulfate Injection (VSI) in the Induction, Intensification, and Maintenance Phases of Combination Chemotherapy in the Treatment of Subjects> 60 Years Old With Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)  III Rose Hoyt  Nebraska Medical Center, Omaha, NE
 CLL A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS=1101) in Combination with Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia  III Susan Blumel  Nebraska Medical Center, Omaha, NE
 AML A Randomized, Multi-Center, Phase III Study of Allogeneic Stem Cell Transplantation Comparing Regimen Intensity in Patients with Myelodysplastic Syndrome or Acute Myeloid Leukemia  III Penny Hardiman  Nebraska Medical Center, Omaha, NE
         
         

Nebraska Oncology Society
c/o Nebraska Medical Association
Sarah Dunbar
Executive Director
233 South 13th Street Suite 1200
Lincoln, NE 68508
sarahd@nebmed.org (email)
402-474-4472 (phone)
402-474-2198 (fax)

Powered by Wild Apricot Membership Software